Parker Waichman LLP

New NIH Ethics Rules Could Require More Disclosure from Researchers

Biomedical researchers who receive funding from the National Institutes of Health (NIH) may soon have to disclose their financial ties with drug and medical device makers under new ethics rules to be proposed next month. Institutions that receive NIH funding are supposed track such financial relationships; however, recent investigations by Senator Charles Grassley, R-Iowa, indicate […]

Biomedical researchers who receive funding from the National Institutes of Health (NIH) may soon have to disclose their financial ties with <"https://www.yourlawyer.com/practice_areas/defective_drugs">drug and <"https://www.yourlawyer.com/practice_areas/defective_medical_devices">medical device makers under new ethics rules to be proposed next month.

Institutions that receive NIH funding are supposed track such financial relationships; however, recent investigations by Senator Charles Grassley, R-Iowa, indicate that there have been violations or lax enforcement of those rules.

Last July, Grassley asked 23 medical schools for information about their conflicts of interest policies and requirements for disclosure of financial relationships between faculty and the drug industry. In a letter to the schools, Grassley outlined a number of disturbing conflicts on the part of researchers at NIH funded schools, including Emory, Stanford and Harvard universities. In October, the Senator asked NIH to explain how 14 NIH-funded university researchers were able to receive payments from Merck & Co. “to promote its controversial anti-cholesterol drug Vytorin.”

During a recent interview with CSPAN’s “Newsmakers” program, NIH head Francis Collins said he was shocked at some of the conflicts Grassley had revealed. He said that next month, the NIH would propose new ethics rules for biomedical researchers that would require them to disclose their financial ties with industry.

The proposed new rules will also ban the practice of “ghostwriting”. As we’ve reported in the past, ghostwriting involves the act of a drug company producing a journal article aimed at either counteracting criticism of a drug or embellishing its benefits. Usually, a drug maker hires a professional writing company to draft the article, and recruits a physician to sign off as the author. Once the article has been published, drug sales reps often present copies of the piece to physicians as evidence that the drug covered in the article is safe and effective.

Critics of the pharmaceutical industry claim ghostwriting is a common practice. A survey published just last September in the Journal of the American Medical Association found that 7.8 percent of 900 research articles, reviews, or editorials that appeared in six general medical journals in 2008 were written by un-credited ghostwriters. So-called “Honorary Authors” were also listed in about 20.6 percent of medical journal articles the researchers reviewed. An Honorary Author is someone credited with an article, but who in reality contributed very little.

What Our Clients Say About Us
We have worked with thousands of clients and we appreciate them and their positive reviews. Here are just a few recent client reviews...
5 Star Reviews 150
Christina Morace was my amazing, wonderful, brilliant point of contact. She went above and beyond in helping me. Parker Waichman is very lucky to have someone as great as Chritina Morace.
Eddie Beverly
2 months ago
5 Star Reviews 150
I couldn’t say more good things about Daniel Burke. He was there every moment that I needed him. Thank you so very much for all that you did.
Edgar Poole
7 years ago
5 Star Reviews 150
Positive: Professionalism , Responsiveness I am very happy with the services provided by this firm. They were very professional and responsive to my needs and concerns.
Kristan David Curry
3 years ago

Why Choose Us to Help You?

We Take Care of Everything
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
No Recovery = No Legal Fees
We work on a contingency-fee basis, meaning that we only get paid from a portion of your settlement or jury award. If you don't get compensation, you owe us nothing.
Decades of Experience
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
Respected by Our Peers
Judges, insurance adjusters, and fellow attorneys all speak highly of our skills, and we've earned numerous accolades, including a flawless rating from AVVO.
We Have Many Locations To Serve You
We have the experience and the skilled litigators to win your case. Contact us and speak with a real attorney who can help you.
Long Island – Nassau
Parker Waichman LLP
6 Harbor Park Drive
Port Washington, NY 11050
Long Island – Suffolk
Parker Waichman LLP
201 Old Country Road – Suite 145
Melville, NY 11747
New York
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038
Queens
Parker Waichman LLP
118-35 Queens Boulevard, Suite 400
Forest Hills, NY 11375
Brooklyn
Parker Waichman LLP
300 Cadman Plaza West
One Pierrepont Plaza, 12th Floor
Brooklyn, NY 11201
New Jersey
Parker Waichman LLP
80 Main Street, Suite 265
West Orange, NJ 07052
Florida
Parker Waichman LLP
27299 Riverview Center Boulevard
Suite 108
Bonita Springs, FL 34134
Nationwide Service
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038